A federal program designed to help get struggling businesses back on their feet after economic losses related to COVID-19 went live today (April 3), and experts say the time to act is now if an entity believes it has been, or will be, significantly negatively impacted by COVID-19 repercussions

The spirit of sharing and caring is visible in the clinical trial industry, where numerous service providers and other professionals are stepping up by donating valuable time and insights to help battle the deadly COVID-19 pandemic.

The U.S. Food and Drug Administration (FDA) yesterday (March 31) unveiled the Coronavirus Treatment Acceleration Program (CTAP), which is designed to use “every tool at the agency’s disposal to bring new therapies to sick patients as quickly as possible, while at the same time supporting research to further evaluate whether these medical countermeasures are safe and effective for treating patients infected with this novel virus.”